CSS
SYRE icon

Cubist Systematic Strategies’s Spyre Therapeutics SYRE Stock Holding History

Cubist Systematic Strategies’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,303
Closed -$1.87M – 3973
2024
Q1 		$1.87M Buy
49,303
+23,153
+89% +$671K 0.01% 1696
2023
Q4 		$563K Buy
+26,150
New +$360K ﹤0.01% 2458
2022
Q2 		– Sell
-484
Closed -$28K – 4567
2022
Q1 		$28K Sell
484
-1,754
-78% -$147K ﹤0.01% 3450
2021
Q4 		$266K Buy
+2,238
New +$353K ﹤0.01% 2883
2021
Q3 		– Sell
-469
Closed -$82K – 3167
2021
Q2 		$82K Sell
469
-244
-34% -$44.3K ﹤0.01% 2737
2021
Q1 		$141K Buy
713
+345
+94% +$66.2K ﹤0.01% 2575
2020
Q4 		$72K Buy
368
+12
+3% +$2.49K ﹤0.01% 2437
2020
Q3 		$63K Sell
356
-70
-16% -$12.9K ﹤0.01% 2346
2020
Q2 		$98K Buy
+426
New +$81.1K ﹤0.01% 2197
2018
Q3 		– Sell
-494
Closed -$131K – 2073
2018
Q2 		$131K Buy
+494
New +$122K 0.01% 1464

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Cubist Systematic Strategies's SYRE Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 49,303 shares — an estimated $1.87M sold.

Cubist Systematic Strategies first reported a position in SYRE in Q2 2018 and held it in 10 quarters. The position peaked at $1.87M in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 49,303 Spyre Therapeutics shares in Q2 2024, an estimated $1.87M.
  • Cubist Systematic Strategies first reported a position in Spyre Therapeutics in Q2 2018 and held it in 10 quarters.
  • Cubist Systematic Strategies's Spyre Therapeutics position peaked at $1.87M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.